# Carcinoma of the Renal Pelvis and Ureter Histopathology Reporting Proforma

(NEPHROURETERECTOMY AND URETERECTOMY)

Includes the International Collaboration on Cancer reporting dataset denoted by *

<table>
<thead>
<tr>
<th>Family name</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Given name(s)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Date of birth</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>DD – MM – YYYY</td>
<td>--</td>
</tr>
</tbody>
</table>

**Indigenous Status**
- Aboriginal but not Torres Strait Islander origin
- Torres Strait Islander but not Aboriginal origin
- Both Aboriginal and Torres Strait Islander origin
- Neither Aboriginal nor Torres Strait Islander origin
- Not stated/inadequately described

**CLINICAL INFORMATION**

**Previous history of urinary tract disease or distant metastasis**
- Information not provided
- No previous history
- Non-invasive papillary
- Carcinoma in situ, flat
- Invasion into lamina propria
- Muscle invasive disease
- Distant metastasis
- Other, specify

**Previous therapy**
- Information not provided
- No previous therapy
- Radiation therapy
- Chemotherapy, systemic
- Bacillus Calmette-Guerin (BCG)
- Chemotherapy, intravesical, specify
- Other, specify

**Other clinical information**

**OPERATIVE PROCEDURE**
- Not specified
- Nephroureterectomy
- Ureterectomy, partial
- Ureterectomy, complete
- Ureterectomy with cystectomy
- Ureterectomy with cystoprostatectomy
- Other, specify

**ADDITIONAL SPECIMEN(S) SUBMITTED**

- Not submitted

**PRINCIPAL CLINICIAN**

**OTHER CLINICAL INFORMATION RECEIVED**

---

Vers. 1.0 Proforma: Carcinoma of the Renal Pelvis and Ureter Structured Reporting Protocol 1st Edition  
Page 1 of 6
### Macroscopic findings

**S2.01** SPECIMEN LABELLED AS

- [ ]

**S2.02** *OPERATIVE PROCEDURE*
- [ ] Not specified
- [ ] Nephroureterectomy
- [ ] Ureterectomy, partial
- [ ] Ureterectomy, complete
- [ ] Ureterectomy with cystectomy
- [ ] Ureterectomy with cystoprostatectomy
- [ ] Other, specify

**S2.03** *ADDITIONAL SPECIMEN(S) SUBMITTED*

- [ ] Not submitted

**S2.04** SPECIMEN MEASUREMENTS
( Superior to inferior x transverse x anterior to posterior)

<table>
<thead>
<tr>
<th></th>
<th>length mm</th>
<th>width mm</th>
<th>thickness mm</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

LENGTH OF URETERS

<table>
<thead>
<tr>
<th></th>
<th>Left mm</th>
<th>Right mm</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**MEASUREMENTS OF OTHER ORGANS**

- **Organ 1:**
  - [ ]
  - [ ] length mm | width mm | thickness mm
- **Organ 2:**
  - [ ]
  - [ ] length mm | width mm | thickness mm
- **Organ 3:**
  - [ ]
  - [ ] length mm | width mm | thickness mm

**S2.05** *TUMOUR FOCALITY*

- [ ] Cannot be assessed, specify
- [ ] Unifocal
- [ ] Multifocal

**S2.06** *MACROSCOPIC TUMOUR SITE*
(select all that apply)

- [ ] Indeterminate
- [ ] No macroscopically visible tumour
- [ ] Ureter
- [ ] Renal pelvis
- [ ] Other, specify

**S2.07** *TUMOUR DIMENSIONS*

- [ ] Cannot be assessed
- [ ] No macroscopically visible tumour

Maximum tumour dimension
(largest tumour)

<table>
<thead>
<tr>
<th></th>
<th>mm</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**G2.02** *Additional dimensions (largest tumour)*

<table>
<thead>
<tr>
<th></th>
<th>mm</th>
<th>mm</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**G2.03** GROSS APPEARANCE OF TUMOUR(S)
(Record for each tumour) (select all that apply)

- **Tumour 1:**
  - [ ] Polypoid
  - [ ] Fungating
  - [ ] Papillary
  - [ ] Ulcerated
  - [ ] Solid and indurated
- **Tumour 2:**
  - [ ] Polypoid
  - [ ] Fungating
  - [ ] Papillary
  - [ ] Ulcerated
  - [ ] Solid and indurated
- **Tumour 3:**
  - [ ] Polypoid
  - [ ] Fungating
  - [ ] Papillary
  - [ ] Ulcerated
  - [ ] Solid and indurated
### S2.08 MACROSCOPIC EXTENT OF INVASION
(Select all that apply)
- Cannot be assessed
- No macroscopically visible tumour
- Non-invasive tumour visible
- Invasion into wall
- Invasion into periureteral/peri pelvic tissue
- Invasion into renal stroma
- Invasion into perinephric fat
- Involvement of other adjacent structures, specify

### S2.09 MACROSCOPIC EVIDENCE OF MARGIN INVOLVEMENT
- Absent
- Present

**MARGIN INVOLVED** (Select all that apply)
- Renal hilar
- Perinephric fat
- Ureteric
- Periureteric

### S2.04 APPEARANCE OF UNINVOLVED TISSUE
- Normal
- Ulcerated
- Erythematous
- Other, specify

### S2.10 LYMPH NODES
- Not submitted
- Submitted

<table>
<thead>
<tr>
<th>Site(s) and ....</th>
<th>No. of nodes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### S2.11 BLOCK IDENTIFICATION KEY

### G2.05 OTHER MACROSCOPIC COMMENTS

### Microscopic findings

### S3.01 HISTOLOGICAL TUMOUR TYPE
- Urothelial carcinoma
- Squamous cell carcinoma
- Adenocarcinoma
- Tumours of Müllerian type
  - Clear cell carcinoma
  - Endometrioid carcinoma
- Neuroendocrine tumour
  - Small cell neuroendocrine carcinoma
  - Large cell neuroendocrine carcinoma
- Other, specify

**Histological sub-type/variant (urothelial carcinoma)**
- Not identified
- Present, specify sub-type/variant and percentage

<table>
<thead>
<tr>
<th>Type</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Squamous</td>
<td></td>
</tr>
<tr>
<td>Glandular</td>
<td></td>
</tr>
<tr>
<td>Nested</td>
<td></td>
</tr>
<tr>
<td>Micropapillary</td>
<td></td>
</tr>
<tr>
<td>Plasmacytoid</td>
<td></td>
</tr>
<tr>
<td>Sarcomatoid</td>
<td></td>
</tr>
<tr>
<td>Other, specify</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Site(s) and ....</th>
<th>No. of nodes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
S3.02 **NON-INVASIVE CARCINOMA**
(select all that apply)
- Not identified
- Indeterminate
- Carcinoma in situ, flat
  - Focal
  - Multifocal
- Papillary carcinoma, non-invasive
- Other, specify

G3.01 **ASSOCIATED EPITHELIAL LESIONS**
- Not identified
- Present, specify

S3.03 **HISTOLOGICAL GRADE**
- Not applicable
- Cannot be determined

Urothelial carcinoma
- Low-grade
- High-grade
- Other, specify

Squamous cell ca. or adenocarcinoma
- GX: Cannot be assessed
- G1: Well differentiated
- G2: Moderately differentiated
- G3: Poorly differentiated
- Other, specify

S3.04 **MICROSCOPIC EXTENT OF INVASION**
(select all that apply)
- Cannot be assessed
- No evidence of primary tumour
- Papillary carcinoma, non-invasive
- Carcinoma in situ, flat
- Tumour invades subepithelial connective tissue (lamina propria)
- Tumour invades the muscularis propria
- Tumour invades beyond muscularis propria into periureteric or peripelvic (renal sinus) fat
- Tumour invades into the renal stroma
- Tumour invades through the kidney into the perinephric fat
- Tumour invades adjacent structures, specify

S3.05 **MICROSCOPIC TUMOUR SITE(S)**
(select all that apply)
- Renal pelvis, specify
- Ureter, specify
- Kidney, specify
- Pelvicalyceal, specify

G3.02 **TUMOUR SIZE** (maximum dimension of the largest tumour)

S3.06 **LYMPHOVASCULAR INVASION**
- Not identified
- Present
- Indeterminate

S3.07 **MARGIN STATUS**
- Cannot be assessed
- Not involved
- Involved
  - Invasive carcinoma
    - Renal hilar
    - Perinephric fat
    - Ureteric
    - Periureteric
    - Distal
    - Proximal
    - Other, specify
  - Carcinoma in situ/non-invasive high-grade urothelial carcinoma
    - Distal mucosal
    - Proximal mucosa
    - Other, specify
**S3.08 REGIONAL LYMPH NODES STATUS**
- No regional nodes submitted
- Not involved (record no. of LN examined)
- Involved

  Number of lymph nodes examined
  
  No. of positive lymph nodes
  - Number cannot be determined

  Size of largest metastasis
  - mm

  Location(s) of involved lymph nodes

**S3.09 HISTOLOGICALLY CONFIRMED DISTANT METASTASES**
- Not identified
- Indeterminate
- Present, specify site(s)

**S3.10 COEXISTENT PATHOLOGY**
- Non-neoplastic renal tissue
  - Not applicable
  - Insufficient tissue
  - No significant pathologic alterations
  - Significant pathologic alterations, specify

  Other histopathological features
  - None identified
  - Present, specify

**G3.04 OTHER MICROSCOPIC COMMENT**

**Ancillary findings**

**G4.01 ANCILLARY STUDIES**
- Not performed
- Performed
  Describe

**Synthesis and overview**

**S5.01 PATHOLOGICAL STAGING AJCC TNM 8TH EDITION (refer next page)**

**S5.02 YEAR AND EDITION OF STAGING SYSTEM**

**G5.01 DIAGNOSTIC SUMMARY**
Include Operative procedure and any additional specimens, Tumour type with different subtypes specified, Tumour grade, Tumour extent (Level of invasion), Tumour site, Lymphovascular invasion, Surgical margin status (completeness of excision), Lymph node involvement, Tumour stage, Presence of non-invasive carcinoma

**S5.03 OVERARCHING COMMENT**

**G5.02 CARCINOMA OF THE RENAL PELVIS AND URETER (NEPHROURETERECTOMY AND URETERECTOMY) STRUCTURED REPORTING PROTOCOL (1st Edition 2018)**
**AJCC 8TH EDITION**

m - multiple primary tumours  
r - recurrent  
y - post neoadjuvant therapy

**Primary tumour (pT)**
- TX Primary tumour cannot be assessed  
- T0 No evidence of primary tumour  
- Ta Papillary non invasive carcinoma  
- Tis Carcinoma in situ  
- T1 Tumour invades subepithelial connective tissue  
- T2 Tumour invades the muscularis  
- T3  
  For renal pelvis only: Tumour invades beyond muscularis into peripelvic fat or into the renal parenchyma**
  For ureter only: Tumour invades beyond muscularis into perinephric fat  
- T4 Tumour invades adjacent organs, or through the kidney into the perinephric fat  
** use of terminology is incorrect. Stroma should be substituted for parenchyma.

**Regional lymph nodes (pN)**
- NX Regional lymph nodes cannot be assessed  
- N0 No lymph node metastasis  
- N1 Metastasis in a single lymph node, ≤2 cm in greatest dimension  
- N2 Metastasis in a single lymph node, >2 cm; or multiple lymph nodes